Cargando…

Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke

BACKGROUND: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yuyou, Gu, Shanshan, Han, Ziping, Yang, Zhenghong, Zhong, Liyuan, Li, Lingzi, Wang, Rongliang, Yan, Feng, Luo, Yumin, Borlongan, Cesario, Lu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547350/
https://www.ncbi.nlm.nih.gov/pubmed/37655472
http://dx.doi.org/10.1161/JAHA.123.029817
_version_ 1785115043657940992
author Huang, Yuyou
Gu, Shanshan
Han, Ziping
Yang, Zhenghong
Zhong, Liyuan
Li, Lingzi
Wang, Rongliang
Yan, Feng
Luo, Yumin
Borlongan, Cesario
Lu, Jie
author_facet Huang, Yuyou
Gu, Shanshan
Han, Ziping
Yang, Zhenghong
Zhong, Liyuan
Li, Lingzi
Wang, Rongliang
Yan, Feng
Luo, Yumin
Borlongan, Cesario
Lu, Jie
author_sort Huang, Yuyou
collection PubMed
description BACKGROUND: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant tissue plasminogen activator) based on arterial thrombectomy could improve the prognosis of patients with acute ischemic stroke, but it could not reduce the incidence of recanalization‐related adverse effects. Recently, selective brain hypothermia has been shown to offer neuroprotection against stroke. To enhance the recanalization rate of ischemic stroke and reduce the adverse effects such as tiny thrombosis, brain edema, and hemorrhage, we described for the first time a combined approach of hypothermia and thrombolysis via intraarterial hypothermic rtPA. METHODS AND RESULTS: We initially established the optimal regimen of hypothermic rtPA in adult rats subjected to middle cerebral artery occlusion. Subsequently, we explored the mechanism of action mediating hypothermic rtPA by probing reduction of brain tissue temperature, attenuation of blood–brain barrier damage, and sequestration of inflammation coupled with untargeted metabolomics. Hypothermic rtPA improved neurological scores and reduced infarct volume, while limiting hemorrhagic transformation in middle cerebral artery occlusion rats. These therapeutic outcomes of hypothermic rtPA were accompanied by reduced brain temperature, glucose metabolism, and blood–brain barrier damage. A unique metabolomic profile emerged in hypothermic rtPA‐treated middle cerebral artery occlusion rats characterized by downregulated markers for energy metabolism and inflammation. CONCLUSIONS: The innovative use of hypothermic rtPA enhances their combined, as opposed to stand‐alone, neuroprotective effects, while reducing hemorrhagic transformation in ischemic stroke.
format Online
Article
Text
id pubmed-10547350
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105473502023-10-04 Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke Huang, Yuyou Gu, Shanshan Han, Ziping Yang, Zhenghong Zhong, Liyuan Li, Lingzi Wang, Rongliang Yan, Feng Luo, Yumin Borlongan, Cesario Lu, Jie J Am Heart Assoc Original Research BACKGROUND: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant tissue plasminogen activator) based on arterial thrombectomy could improve the prognosis of patients with acute ischemic stroke, but it could not reduce the incidence of recanalization‐related adverse effects. Recently, selective brain hypothermia has been shown to offer neuroprotection against stroke. To enhance the recanalization rate of ischemic stroke and reduce the adverse effects such as tiny thrombosis, brain edema, and hemorrhage, we described for the first time a combined approach of hypothermia and thrombolysis via intraarterial hypothermic rtPA. METHODS AND RESULTS: We initially established the optimal regimen of hypothermic rtPA in adult rats subjected to middle cerebral artery occlusion. Subsequently, we explored the mechanism of action mediating hypothermic rtPA by probing reduction of brain tissue temperature, attenuation of blood–brain barrier damage, and sequestration of inflammation coupled with untargeted metabolomics. Hypothermic rtPA improved neurological scores and reduced infarct volume, while limiting hemorrhagic transformation in middle cerebral artery occlusion rats. These therapeutic outcomes of hypothermic rtPA were accompanied by reduced brain temperature, glucose metabolism, and blood–brain barrier damage. A unique metabolomic profile emerged in hypothermic rtPA‐treated middle cerebral artery occlusion rats characterized by downregulated markers for energy metabolism and inflammation. CONCLUSIONS: The innovative use of hypothermic rtPA enhances their combined, as opposed to stand‐alone, neuroprotective effects, while reducing hemorrhagic transformation in ischemic stroke. John Wiley and Sons Inc. 2023-09-01 /pmc/articles/PMC10547350/ /pubmed/37655472 http://dx.doi.org/10.1161/JAHA.123.029817 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Huang, Yuyou
Gu, Shanshan
Han, Ziping
Yang, Zhenghong
Zhong, Liyuan
Li, Lingzi
Wang, Rongliang
Yan, Feng
Luo, Yumin
Borlongan, Cesario
Lu, Jie
Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
title Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
title_full Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
title_fullStr Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
title_full_unstemmed Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
title_short Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
title_sort cold case of thrombolysis: cold recombinant tissue plasminogen activator confers enhanced neuroprotection in experimental stroke
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547350/
https://www.ncbi.nlm.nih.gov/pubmed/37655472
http://dx.doi.org/10.1161/JAHA.123.029817
work_keys_str_mv AT huangyuyou coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT gushanshan coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT hanziping coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT yangzhenghong coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT zhongliyuan coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT lilingzi coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT wangrongliang coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT yanfeng coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT luoyumin coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT borlongancesario coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke
AT lujie coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke